Evidence map›Paper›PMID 36888927›Full record

ArticleThe Journal of urology2023

Characterization of Stone Events in Patients With Type 3 Primary Hyperoxaluria.

Muhammad G Arnous, Lisa Vaughan, Ramila A Mehta, Phillip J Schulte, John C Lieske, Dawn S Milliner

Open access · greenAbstract read
In one paragraph

Article in The Journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Genetic and Clinical Characterization of a Large Cohort with Suspected Monogenic Stone Disease.Clinical journal of the American Society of Nephrology : CJASN · 2025
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Muhammad G ArnousDivison of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
Lisa VaughanDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
Ramila A MehtaDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
Phillip J SchulteDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
John C LieskeDivison of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-0202-5944
Dawn S MillinerDivison of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
Mayo Clinic · USWinnMed · US

Funding

Primary HyperoxaluriaU54DK083908 · NIDDK · MAYO CLINIC ROCHESTER · PI MILLINER, DAWN SCHMAUTZ · 2009 to 2018
$12.3M
An individualized medicine approach to urinary stone diseaseR01DK133171 · NIDDK · MAYO CLINIC ROCHESTER · PI Peter C. Harris, Felix Knauf · 2022 to 2026
$3.0M
Facilitating personalized medicine of monogenic stone patients by genetic characterizationR21TR003174 · NCATS · MAYO CLINIC ROCHESTER · PI HARRIS, PETER C., LIESKE, JOHN C · 2020 to 2021
$437k
NCATS NIH HHS R21 TR003174NIDDK NIH HHS R01 DK133171NIDDK NIH HHS U54 DK083908
6 · The paper itself

Abstract

purposeHallmarks of primary hyperoxaluria type 3 are nephrolithiasis and hyperoxaluria. However, little is known about factors influencing stone formation in this disease. We characterized stone events and examined associations with urine parameters and kidney function in a primary hyperoxaluria type 3 population. MATERIALS AND

methodsWe retrospectively analyzed clinical, and laboratory data of 70 primary hyperoxaluria type 3 patients enrolled in the Rare Kidney Stone Consortium Primary Hyperoxaluria Registry.

resultsKidney stones occurred in 65/70 primary hyperoxaluria type 3 patients (93%). Among the 49 patients with imaging available, the median (IQR) number of stones was 4 (2, 5), with largest stone 7 mm (4, 10) at first imaging. Clinical stone events occurred in 62/70 (89%) with median number of events per patient 3 (2, 6; range 1-49). Age at first stone event was 3 years (0.99, 8.7). Lifetime stone event rate was 0.19 events/year (0.12, 0.38) during follow-up of 10.7 (4.2, 26.3) years. Among 326 total clinical stone events, 139 (42.6%) required surgical intervention. High stone event rates persisted for most patients through the sixth decade of life. Analysis was available for 55 stones: pure calcium oxalate accounted for 69%, with mixed calcium oxalate and phosphate in 22%. Higher calcium oxalate supersaturation was associated with increased lifetime stone event rate after adjusting for age at first event (IRR [95%CI] 1.23 [1.16, 1.32];

conclusionsStones impose a lifelong burden on primary hyperoxaluria type 3 patients. Reducing urinary calcium oxalate supersaturation may reduce event frequency and surgical intervention.

Indexed as

HyperoxaluriaHyperoxaluria, PrimaryKidney CalculiCalcium OxalateChild, PreschoolHumansRetrospective StudiesCalcium Oxalate4-hydroxy-2-oxoglutarate aldolasechronichyperoxaluriakidney calculiprimaryrenal insufficiency

Identifiers

PMID36888927
PMCPMC11034812
OpenAlexW4323538912

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.